Tsubota Laboratory（4890 TSE Growth）
＋English Summary on This Page
Develops Medicines and Medical Devices Utilizing Research in Ophthalmology Field
Tsubota Laboratory is a venture company out of Keio University aiming to develop new medicines and medical devices in the field of ophthalmology concerning myopia, dry eyes and presbyopia.
In 2017, when Kazuo Tsubota, president, was a professor at Keio University, he discovered that violet light (visible light with a wavelength of 360nm to 400nm) was effective in preventing myopia. Furthermore, he unraveled the mechanism of violet light suppressing the progression of myopia by increasing blood flow in the eyes, and turned the treatment methods based on a series of discoveries into intellectual properties by acquiring patents, etc. These intellectual properties serve as the company’s technology base, leading to the development of medicines and medical devices to suppress the progression of myopia among children, on which it currently focuses.
Business Model
The company’s business model is a B2B business model in which the company turns research and development achievements into intellectual properties by acquiring patents, etc., enters into joint research and development agreements for development of medicines and medical devices and patent license agreements with the partner companies, and then receives upfront payments, license fees and milestone income.
After product commercialization, the partner companies conduct sales and the company receives royalty income from the royalty agreements. Furthermore, the company invests the income received from the partner companies into deepening ongoing research as well as in new research fields to create new value.
Pipeline of Medicines and Medical Devices and Commodity Products Currently Sold
The company currently has six pipelines in medicines and medical devices (or eight pipelines in adaptive fields). In addition, with commodity products which are already being sold by the partner companies, the company earns royalty income.
Tsubota Laboratory is a venture company out of Keio University aiming to develop new medicines and medical devices in the field of ophthalmology concerning myopia, dry eyes and presbyopia.
In 2017, when Kazuo Tsubota, president, was a professor at Keio University, he discovered that violet light (visible light with a wavelength of 360nm to 400nm) was effective in preventing myopia. Furthermore, he unraveled the mechanism of violet light suppressing the progression of myopia by increasing blood flow in the eyes, and turned the treatment methods based on a series of discoveries into intellectual properties by acquiring patents, etc. These intellectual properties serve as the company’s technology base, leading to the development of medicines and medical devices to suppress the progression of myopia among children, on which it currently focuses.
Business Model
The company’s business model is a B2B business model in which the company turns research and development achievements into intellectual properties by acquiring patents, etc., enters into joint research and development agreements for development of medicines and medical devices and patent license agreements with the partner companies, and then receives upfront payments, license fees and milestone income.
After product commercialization, the partner companies conduct sales and the company receives royalty income from the royalty agreements. Furthermore, the company invests the income received from the partner companies into deepening ongoing research as well as in new research fields to create new value.
Pipeline of Medicines and Medical Devices and Commodity Products Currently Sold
The company currently has six pipelines in medicines and medical devices (or eight pipelines in adaptive fields). In addition, with commodity products which are already being sold by the partner companies, the company earns royalty income.
概要（レポートから抜粋）
坪田ラボ（以下、同社）は、近視、ドライアイ、老眼の眼科領域を対象に、新たな医薬品、医療機器の開発を目指す慶應義塾大学発のベンチャー企業である。
17年に同社の坪田一男社長が教授を務めていた慶應義塾大学医学部眼科教室で、バイオレットライト（波長360～400nmの可視光）が近視の予防に効果があることを発見した。
更に、バイオレットライトが眼の血流を増大させて近視進行を抑制するメカニズムを解明し、これら一連の発見に基づく治療法を特許等として知財化した。
これらの知財が同社の技術基盤となっており、現在注力している、子供の近視の進行を抑制する医薬品、医療機器の開発へとつながっている
同社の事業セグメントは、研究開発事業の単一セグメントであるが、事業モデルとしては、大学等での研究開発成果を特許等として知財化し、パートナー企業と医薬品や医療機器開発のための共同研究開発契約及び特許の実施許諾契約を締結し、契約一時金、実施許諾料、マイルストーン収入を得るB to Bの事業モデルである。
製品事業化（上市）後はパートナー企業が販売を行い、同社はロイヤリティ契約によるロイヤリティ収入を得る。また、パートナー企業からの収益を、既存研究の深化や新しい研究領域に投資することで、新たな価値創造につなげている。
17年に同社の坪田一男社長が教授を務めていた慶應義塾大学医学部眼科教室で、バイオレットライト（波長360～400nmの可視光）が近視の予防に効果があることを発見した。
更に、バイオレットライトが眼の血流を増大させて近視進行を抑制するメカニズムを解明し、これら一連の発見に基づく治療法を特許等として知財化した。
これらの知財が同社の技術基盤となっており、現在注力している、子供の近視の進行を抑制する医薬品、医療機器の開発へとつながっている
同社の事業セグメントは、研究開発事業の単一セグメントであるが、事業モデルとしては、大学等での研究開発成果を特許等として知財化し、パートナー企業と医薬品や医療機器開発のための共同研究開発契約及び特許の実施許諾契約を締結し、契約一時金、実施許諾料、マイルストーン収入を得るB to Bの事業モデルである。
製品事業化（上市）後はパートナー企業が販売を行い、同社はロイヤリティ契約によるロイヤリティ収入を得る。また、パートナー企業からの収益を、既存研究の深化や新しい研究領域に投資することで、新たな価値創造につなげている。
